USA flag logo/image

An Official Website of the United States Government

Biodegradable polymeric iodine contrast agents for CT angiography.

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
R43HL117473
Solicitation Year:
2013
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA12-088
Small Business Information
NANOPROBES, INC.
95 HORSEBLOCK RD YAPHANK, NY 11980-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2013
Title: Biodegradable polymeric iodine contrast agents for CT angiography.
Agency: HHS
Contract: 1R43HL117473-01
Award Amount: $237,184.00
 

Abstract:

DESCRIPTION (provided by applicant): Recent advances in micro-CT machines have made it possible to image with a resolution of lt10 m. Scans take ~6 to 20 minutes to acquire, and current iodine contrast agents due to their short half-lives are not generally suitable. We recentl commercialized non-toxic gold X-ray contrast agent, AuroVist , but they are lot more expensive than iodine agents and their whole body clearance is very slow. We now propose biodegradable polymeric contrast agents that are composed of FDA approved components: hyaluronic acid or polylactide/polyglycolide and a derivative of iodine agent Iobitridol that are lot cheaper than our gold-based contrast agents and more absorptive than conventional iodine agents. The new agents can be labeledwith additional contrast agents, such as gadolinium or iron oxide, enabling multimodal imaging or double contrasting with dual-beam/dual-detector CT. When labeled with iodine agents and targeting molecules will enable in vivo visualization of organ function, angiogenesis, repair, tumor formation, metastasis, studies of response to drugs and other therapies or conditions, such as ischemia or radiation, and basic biological studies of animals including development, infection, immune response, cardiac studies, tissue injury and healing. The new contrast agents will provide more than four times the radiodensity as compared to the conventional iodine contrast agents and will enable longer imaging times as they are intravascular. These agents will more accurately identify vulnerable plaque by clearly identifying lipid core volume as a percentage of plaque volume, angiogenesis/inflammation, and stenoses, among other risk factors. In addition, their higher radiodensity will enable better imaging of obese patients,reduce radiation dose in normal sized patients and reduce nephrotoxicity to permit use in kidney compromised patients. These capabilities go beyond what other agents offer and if clinically implemented could, through screening, reduce the prevalence of coronary artery disease deaths. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposed novel biodegradable polymeric contrast agents for computed tomography will provide higher contrast than conventional iodine agents, reduce X-ray doses tomillions of patents, and when used with gadolinium agents will enable multimodal imaging and double contrasting.

Principal Investigator:

Vishwas N. Joshi
631-205-1682
vnjoshi@nanoprobes.com

Business Contact:

Victoria Kowalski
631-205-9490
kowalski@nanoprobes.com
Small Business Information at Submission:

NANOPROBES, INC.
95 HORSEBLOCK RD YAPHANK, NY 11980-

EIN/Tax ID: 111303845
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No